# Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)

> **NCT01532973** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 48 (actual)

## Conditions studied

- Hepatitis, Viral, Human

## Interventions

- **DRUG:** Elbasvir
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01532973
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02-16
- **Primary completion:** 2013-05-17
- **Final completion:** 2013-05-17
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2018-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01532973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01532973, "Safety, Pharmacokinetics and Pharmacodynamics of Elbasvir (MK-8742) in Hepatitis C Infected Males (MK-8742-002)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT01532973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*